In a report released yesterday, Kostas Biliouris from BMO Capital maintained a Buy rating on Legend Biotech (LEGN – Research Report), ...
Legend Biotech (LEGN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Mitchell ...
Investor's Business Daily on MSN3h
Legend Biotech Rises After J&J-Tied Cancer Drug Cuts Risk Of Death By 45%Legend Biotech jumped Monday after the company said its J&J-tied multiple myeloma drug, Cavykti, cut the risk of death.
After putting on a strong performance in preventing disease progression in the earlier treatment of multiple myeloma, Johnson ...
Johnson & Johnson and Legend Biotech presented new data from the Phase 3 CARTITUDE-4 study, showing Carvykti significantly ...
Johnson & Johnson linked Carvykti to a 45% reduction in risk of death and Darzalex to a 61% improvement in minimal residual ...
Johnson & Johnson reported long-term Phase III CARTITUDE-4 study results showing that a single infusion of Carvykti ...
"Johnson & Johnson’s CARVYKTI improves survival in multiple myeloma trial" was originally created and published by Clinical ...
DREAM Pivotal Study Data Presented at the International Surgical Sleep Society 2024 Educational Update ...
Johnson & Johnson and Legend Biotech's CAR-T cell therapy Carvykti reduced the risk of death by 45% compared to standard of ...
Binod Dhakal, MD, MS, discusses some of the challenges often seen in the myeloma space, particularly those with lenalidomide-refractory multiple myeloma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback